These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8398843)

  • 21. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study.
    Meyer G; Brenot F; Pacouret G; Simonneau G; Gillet Juvin K; Charbonnier B; Sors H
    Thromb Haemost; 1995 Dec; 74(6):1432-5. PubMed ID: 8772215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Lim W; Dentali F; Eikelboom JW; Crowther MA
    Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.
    Levine M; Gent M; Hirsh J; Leclerc J; Anderson D; Weitz J; Ginsberg J; Turpie AG; Demers C; Kovacs M
    N Engl J Med; 1996 Mar; 334(11):677-81. PubMed ID: 8594425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
    Cavusoglu E; Lakhani M; Marmur JD
    J Invasive Cardiol; 2005 Aug; 17(8):416-21. PubMed ID: 16079447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.
    Massicotte P; Adams M; Marzinotto V; Brooker LA; Andrew M
    J Pediatr; 1996 Mar; 128(3):313-8. PubMed ID: 8774496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Avoiding intelligence failures in the cardiac catheterization laboratory: Strategies for the safe and rational use of dalteparin or enoxaparin during percutaneous coronary intervention.
    Marmur JD; Bullock-Palmer RP; Poludasu S; Cavusoglu E
    J Invasive Cardiol; 2009 Dec; 21(12):653-64. PubMed ID: 19966370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed cutaneous reaction to unfractionated heparin, low molecular weight heparin and danaparoid.
    Sivakumaran M; Ghosh K; Munks R; Gelsthorpe K; Tan L; Wood JK
    Br J Haematol; 1994 Apr; 86(4):893-4. PubMed ID: 7802799
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clexane (enoxaprin) or Fragmin (dalteparin) for thrombolytic prevention in hip replacement surgery?].
    Gjengedal E; Uppheim G
    Tidsskr Nor Laegeforen; 1996 Jun; 116(15):1782-4. PubMed ID: 8693460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse skin reactions to low molecular weight heparins: frequency, management and prevention.
    Wütschert R; Piletta P; Bounameaux H
    Drug Saf; 1999 Jun; 20(6):515-25. PubMed ID: 10392668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Determination of anti-Xa activity in cancer patients].
    Somonova OV; Madzhuga AV; Elizarova AL; Zubrikhina GN
    Klin Lab Diagn; 2008 Nov; (11):24, 33-4. PubMed ID: 19140408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Skin reactions due to low molecular weight heparin in pregnancy: a strategic dilemma.
    Verdonkschot AE; Vasmel WL; Middeldorp S; van der Schoot JT
    Arch Gynecol Obstet; 2005 Feb; 271(2):163-5. PubMed ID: 15112083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
    Bergmann JF; Neuhart E
    Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment in a heparin-induced skin reaction with a low-molecular heparin analog].
    Zimmermann R; Harenberg J; Weber E; DeVries JX; Jarass W; Schmidt W
    Dtsch Med Wochenschr; 1984 Aug; 109(35):1326-8. PubMed ID: 6236069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.
    Fiessinger JN; Lopez-Fernandez M; Gatterer E; Granqvist S; Kher A; Olsson CG; Söderberg K
    Thromb Haemost; 1996 Aug; 76(2):195-9. PubMed ID: 8865530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Clinical Practice: Low-Molecular-Weight Heparins in The Prophylaxis and Treatment of Thrombo-Embolic Disease.
    O'shaughnessy DF
    Hematology; 1999; 4(5):373-80. PubMed ID: 27426841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prospective randomized study comparing the effectiveness and tolerance of various low-molecular-weight heparins in high risk patients].
    Janni W; Bergauer F; Rjosk D; Lohscheidt K; Hagena FW
    Zentralbl Chir; 2001 Jan; 126(1):32-8. PubMed ID: 11227291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).
    Klein W; Buchwald A; Hillis SE; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
    Circulation; 1997 Jul; 96(1):61-8. PubMed ID: 9236418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.